Possible roles of actin and myosin during anaphase chromosome movements in locust spermatocytes.
We tested whether the mechanisms of chromosome movement during anaphase in locust (Locusta migratoria L.) spermatocytes might be similar to those described for crane-fly spermatocytes. Actin and myosin have been implicated in anaphase chromosome movements in crane-fly spermatocytes, as indicated by the effects of inhibitors and by the localisations of actin and myosin in spindles. In this study, we tested whether locust spermatocyte spindles also utilise actin and myosin, and whether actin is involved in microtubule flux. Living locust spermatocytes were treated with inhibitors of actin (latrunculin B and cytochalasin D), myosin (BDM), or myosin phosphorylation (Y-27632 and ML-7). We added drugs (individually) during anaphase. Actin inhibitors alter anaphase: chromosomes either completely stop moving, slow, or sometimes accelerate. The myosin inhibitor, BDM, also alters anaphase: in most cases, the chromosomes drastically slow or stop. ML-7, an inhibitor of MLCK, causes chromosomes to stop, slow, or sometimes accelerate, similar to actin inhibitors. Y-27632, an inhibitor of Rho-kinase, drastically slows or stops anaphase chromosome movements. The effects of the drugs on anaphase movement are reversible: most of the half-bivalents resumed movement at normal speed after these drugs were washed out. Actin and myosin were present in the spindles in locations consistent with their possible involvement in force production. Microtubule flux along kinetochore fibres is an actin-dependent process, since LatB completely removes or drastically reduces the gap in microtubule acetylation at the kinetochore. These results suggest that actin and myosin are involved in anaphase chromosome movements in locust spermatocytes.
Fabian
Lacramioara
L
Biology Department, York University, Toronto, Ontario, Canada.
Forer
Arthur
A
D000199:Actins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D000705:Anaphase; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D020090:Chromosome Segregation; D002875:Chromosomes / Q000187:drug effects / Q000502:physiology*; D015638:Cytochalasin D / Q000494:pharmacology; D048749:Cytokinesis / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006110:Grasshoppers / Q000166:cytology*; D008297:Male; D008540:Meiosis; D009068:Movement / Q000187:drug effects; D009219:Myosin-Light-Chain Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009218:Myosins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D034521:Nuclear Matrix-Associated Proteins / Q000302:isolation & purification / Q000378:metabolism; D013090:Spermatocytes / Q000166:cytology* / Q000502:physiology / Q000648:ultrastructure; D008941:Spindle Apparatus / Q000378:metabolism / Q000648:ultrastructure; D053778:Thiazolidines / Q000494:pharmacology
D000199:Actins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004791:Enzyme Inhibitors; D034521:Nuclear Matrix-Associated Proteins; D053778:Thiazolidines; D015638:Cytochalasin D; D009219:Myosin-Light-Chain Kinase; D009218:Myosins; C037068:latrunculin B